Calendar
Earnings, material events, systemic alerts, and macro research on one tape.
Window 30d/153 items/As of 2026-10-29
Upcoming
139
Earnings
139
Surprises
6
Post-earnings
6
Event Tape
8
Macro Notes
0
Earnings
139 items
Scheduled reports and post-earnings memos
amc
ALL earnings
Allstate has a confirmed November 4 after-market earnings announcement, consensus of $6.89 EPS and $15.84B revenue, and a reported EPS beat in 7 of its last 8 quarters; however, consensus implies year-over-year EPS and revenue declines, the stock fell about 3.4% over five sessions, recent closes were weak within their daily ranges, and no positive estimate revisions or volume surge were verified.
Allstate Corp Common
amc
MET earnings
MetLife has a confirmed November 4 after-market release and published consensus of $2.77 EPS and $19.86B revenue, with prior-quarter EPS above consensus and positive Q3 expected EPS growth; however, checked sources did not establish positive current-quarter estimate revisions, ESP/whisper upside, or revenue estimate increases, and the recent tape weakened without verified volume accumulation.
MetLife Inc Common
amc
AFL earnings
Aflac shares have advanced over the recent weeks, but checked Q3 consensus implies lower year-over-year EPS and revenue and no positive estimate-revision or revenue-upside signal was found; the latest session also lacked a qualifying close location.
Aflac Inc Common
amc
EW earnings
Edwards has a November 4 earnings date and published Q3 consensus of $0.74 EPS and $1.68B revenue, with a prior-quarter EPS beat and evidence of ongoing product-market growth; the checked sources do not establish positive estimate revisions or revenue upside, and recent volume was not verified at the required threshold.
Edwards Lifesciences Corp Common
amc
VMRK earnings
The company confirmed a Nov 4 after-close Q3 release, and available sources show EPS and revenue consensus estimates. However, no positive estimate revisions or revenue upside evidence was found; VMRK fell 1.6% over five sessions, underperformed the S&P 500, and Oct 28 volume was below normal. Merger integration is a disclosed risk, so this is not a qualifying surprise setup.
Vivmark Residential Common
Time pending
MELI earnings
MercadoLibre's latest reported quarter showed strong revenue acceleration, but the checked pre-event sources do not establish positive EPS revisions/ESP or revenue revisions/upside; the stock also fell sharply during the recent tape window, with the highest-volume session a selloff. Those shortcomings outweigh the longer-term operating growth story.
MercadoLibre Inc Common
Recent Context
Already-happened research items are kept for context, newest first.
Earnings
6 items
Scheduled reports and post-earnings memos
Earnings 2026-10-20
NPB post-earnings memo
The company-confirmed earnings miss and exit announcement dominate current news. A live quote showed approximately $14.64 at 13:34 UTC on October 21, about 7.2% below the $15.78 prior close, but this was an early quote, not a confirmed closing reaction or proof of causation. Verified post-print analyst revisions and a call transcript were unavailable at this T+1 checkpoint. Zero-valued social, options, short-interest, and employee fields denote unavailable data, not measured neutrality.
Northpointe Bancshares
Earnings 2026-10-20
EWBC post-earnings memo
The Q3 release improved the operating evidence, but the modest consensus beat does not by itself justify a strong thesis change. An [early October 21 quote](https://www.investing.com/news/earnings/east-west-bancorp-reports-q3-earnings-and-revenue-above-analyst-expectations-93CH-4961066) and the packet’s $128.27 anchor do not establish whether a post-earnings move will hold. Verified post-print analyst revisions were unavailable. The negative deterministic directional prior therefore warrants continued monitoring despite stronger company guidance.
East West Bancorp
Earnings 2026-10-20
GSHD post-earnings memo
Neutral monitoring view. The deterministic prior is neutral despite strong historical-source quality: Q2 operating evidence is solid, but the purported October 20 earnings event did not occur. There is therefore no Q3 surprise, post-print analyst revision, or earnings-linked price reaction to assess. The packet supplies an October 20 adjusted-close anchor of $47.01; no causation is inferred from that price. Sentiment fields without measured coverage are placeholders, not observed readings.
Goosehead Insurance
Earnings 2026-10-20
WFRD post-earnings memo
The company release confirms a strong sequential quarter and higher cash-flow guidance, preserving the structured prior's positive direction, but year-over-year weakness and Middle East uncertainty limit conviction. A live quote at 13:32 UTC on October 21 was $84.14, about 6.0% above the packet's $79.34 October 20 close; this is an early intraday reaction, not a closing return or proof of a durable re-rating. [WFRD quote](https://finance.yahoo.com/quote/WFRD/) Post-print analyst revisions and call-transcript digestion were not yet verified. Zero-valued sentiment fields denote unavailable measurements, not neutral observations; the packet supplies no sufficient social, options-skew, short-interest or employee-score data. The stored earnings-document row concerns Liberty Energy, not WFRD, and was excluded.
Weatherford International
Earnings 2026-10-20
VKTX post-earnings memo
The packet contains constructive clinical headlines, but no verified October 20 earnings release, earnings-linked price reaction, consensus surprise or post-print analyst revision. Zeroes in unverified sentiment fields denote unavailable data, not neutral measured readings. The $26.71 October 20 anchor is not evidence of a post-release move. The scheduled earnings trigger should therefore be treated as unconfirmed, with the negative deterministic return prior and financing/cash-burn risks tempering the clinical positives.
Viking Therapeutics
Earnings 2026-10-20
VICR post-earnings memo
The stock closed October 20 at the packet's $204.14 anchor, up 7.06% from $190.68 on October 19, following the pre-market release (price history: https://www.financecharts.com/stocks/VICR/summary/price). That is an immediate positive reaction, not proof it will hold. Q3 revenue beat the Zacks pre-release estimate, but its EPS estimate implies a miss; published consensus figures conflict. Post-print analyst revisions and target changes were not verified at this T+1 point. Strong primary-source results warrant updating the prior thesis, but the negative deterministic directional prior, royalty lumpiness and incomplete revision signal still favor monitoring.
Vicor
News & Research
1 item
Material events, systemic alerts, and macro notes

